{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:10:30Z","timestamp":1763644230955,"version":"3.45.0"},"reference-count":22,"publisher":"Danish Medical Association","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ugeskr L\u00e6ger"],"abstract":"<jats:p>Transthyretin amyloidosis (ATTR-CM) is an infiltrative cardiomyopathy caused by the deposition of amyloid fibrils, leading to heart failure, arrhythmias, and increased mortality. ATTR-CM prevalence is rising. The first disease-modifying drugs have been approved and implemented in Denmark. Additional treatments slowing ATTR-CM progression are pending introduction into clinical practice. Treatments halting or even reversing progression are currently being investigated in clinical trials. The new therapies will significantly improve ATTR-CM-associated morbidity and mortality, as argued in this review.<\/jats:p>","DOI":"10.61409\/v04250323","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T13:19:06Z","timestamp":1763558346000},"page":"1-8","source":"Crossref","is-referenced-by-count":0,"title":["Transthyretin amyloid cardiomyopathy"],"prefix":"10.61409","author":[{"given":"Sie Kronborg","family":"Fensman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ali Hussein Jaber","family":"Mejren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tor Skibsted","family":"Clemmensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steen Hvitfeldt","family":"Poulsen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"40208","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Ruberg FL, Grogan M, Hanna M, et al. Transthyretin amyloid cardiomyopathy: JACC state-of-the-art review. J Am Coll Cardiol. 2019;73(22):2872-2891. https:\/\/doi.org\/10.1016\/j.jacc.2019.04.003","DOI":"10.1016\/j.jacc.2019.04.003"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Maurer MS, Falk RH, et al. Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation. 2016;133(24):2404-2412. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.116.021612","DOI":"10.1161\/CIRCULATIONAHA.116.021612"},{"key":"ref2","unstructured":"Spanggard MBL, Hansen CT, Maiborg M, et al. Amyloidose er en sygdom med mange ansigter. Ugeskr L\u00e6ger. 2023;185:V08220479. https:\/\/ugeskriftet.dk\/videnskab\/amyloidose-er-en-sygdom-med-mange-ansigter"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Larsen SB, Ladefoged B, Pedersen ALD, et al. Changes of clinical characteristics, distribution of red flags and prognosis in contemporary patients with wild-type transthyretin amyloidosis cardiomyopathy. Ann Med. 2024;56(1):2398735. https:\/\/doi.org\/10.1080\/07853890.2024.2398735","DOI":"10.1080\/07853890.2024.2398735"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Damy T, Fontana M, et al. A new staging system for cardiac transthyretin amyloidosis. Eur Heart J. 2018;39(30):2799-2806. https:\/\/doi.org\/10.1093\/eurheartj\/ehx589","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Westin O, Butt JH, Gustafsson F, et al. Two decades of cardiac amyloidosis: a Danish nationwide study. JACC CardioOncol. 2021;3(4):522-533. https:\/\/doi.org\/10.1016\/j.jaccao.2021.05.004","DOI":"10.1016\/j.jaccao.2021.05.004"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Gilstrap LG, Dominici F, Wang Y, et al. Epidemiology of cardiac amyloidosis-associated heart failure hospitalizations among fee-for-service Medicare beneficiaries in the United States. Circ Heart Fail. 2019;12(6):e005407. https:\/\/doi.org\/10.1161\/CIRCHEARTFAILURE.118.005407","DOI":"10.1161\/CIRCHEARTFAILURE.118.005407"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Lindmark K, Pilebro B, Sundstr\u00f6m T, Lindqvist P. Prevalence of wild-type transthyretin cardiac amyloidosis in a heart failure clinic. ESC Heart Fail. 2021;8(1):745-749. https:\/\/doi.org\/10.1002\/ehf2.13110","DOI":"10.1002\/ehf2.13110"},{"key":"ref8","unstructured":"Dansk Cardiologisk Selskab. Kardiel amyloidose - et holdningspapir fra Dansk Cardiologisk Selskab, 2024. https:\/\/www.cardio.dk\/media\/com_reditem\/files\/customfield\/item\/8067\/62423808da908d95dd38d36aeef62531909ed81b.pdf (7. juli 2025)"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Ando Y, Waddington-Cruz M, Sekijima Y, et al. Optimal practices for the management of hereditary transthyretin amyloidosis: real-world experience from Japan, Brazil, and Portugal. Orphanet J Rare Dis. 2023;18(1):323. https:\/\/doi.org\/10.1186\/s13023-023-02910-3","DOI":"10.1186\/s13023-023-02910-3"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Maurer MS. Overview of current and emerging therapies for amyloid transthyretin cardiomyopathy. Am J Cardiol. 2022;185(Suppl 1):S23-S34. https:\/\/doi.org\/10.1016\/j.amjcard.2022.10.014","DOI":"10.1016\/j.amjcard.2022.10.014"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med. 2018;379(11):1007-1016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","DOI":"10.1056\/NEJMoa1805689"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Judge DP, Cappelli F, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. N Engl J Med. Jan 11 2024;390(2):132-142. https:\/\/doi.org\/10.1056\/NEJMoa2305434","DOI":"10.1056\/NEJMoa2305434"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Judge DP, Alexander KM, Cappelli F, et al. Efficacy of acoramidis on all-cause mortality and cardiovascular hospitalization in transthyretin amyloid cardiomyopathy. J Am Coll Cardiol. 2025;85(10):1003-1014. https:\/\/doi.org\/10.1016\/j.jacc.2024.11.042","DOI":"10.1016\/j.jacc.2024.11.042"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Maurer MS, Kale P, Fontana M, et al. Patisiran treatment in patients with transthyretin cardiac amyloidosis. N Engl J Med. 2023;389(17):1553-1565. https:\/\/doi.org\/10.1056\/NEJMoa2300757","DOI":"10.1056\/NEJMoa2300757"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Fontana M, Berk JL, Gillmore JD, et al. Vutrisiran in Patients with Transthyretin Amyloidosis with Cardiomyopathy. N Engl J Med. 2025;392(1):33-44. https:\/\/doi.org\/10.1056\/NEJMoa2409134","DOI":"10.1056\/NEJMoa2409134"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Jinek M, Chylinski K, Fonfara I, et al. A programmable dual-RNA-guided DNA endonuclease in adaptive bacterial immunity. Science. 2012;337(6096):816-821. https:\/\/doi.org\/10.1126\/science.1225829","DOI":"10.1126\/science.1225829"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Gillmore JD, Gane E, Taubel J, et al. CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis. N Engl J Med. 2021;385(6):493-502. https:\/\/doi.org\/10.1056\/NEJMoa2107454","DOI":"10.1056\/NEJMoa2107454"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Fontana M, Solomon S, Kachadourian J, et al. CRISPR-Cas9 Gene Editing with Nexiguran Ziclumeran for ATTR Cardiomyopathy. N Engl J Med. 2024;391(23):2231-2241. https:\/\/doi.org\/10.1056\/NEJMoa2412309","DOI":"10.1056\/NEJMoa2412309"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Fontana M, Gilbertson J, Verona G, et al. Antibody-Associated Reversal of ATTR Amyloidosis-Related Cardiomyopathy. N Engl J Med. 2023;388(23):2199-2201. https:\/\/doi.org\/10.1056\/NEJMc2304584","DOI":"10.1056\/NEJMc2304584"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Garcia-Pavia P, Aus dem Siepen F, Donal E, et al. Phase 1 Trial of Antibody NI006 for Depletion of Cardiac Transthyretin Amyloid. N Engl J Med. 2023;389(3):239-250. https:\/\/doi.org\/10.1056\/NEJMoa2303765","DOI":"10.1056\/NEJMoa2303765"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Suhr O, Grogan M, Silva A, et al. PRX004 in variant amyloid transthyretin (ATTRv) amyloidosis: results of a phase 1, open-label, dose-escalation study. Amyloid. 2025;32(1):14-21. https:\/\/doi.org\/10.1080\/13506129.2024.2420809","DOI":"10.1080\/13506129.2024.2420809"}],"container-title":["Ugeskrift for L\u00e6ger"],"original-title":[],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T12:57:46Z","timestamp":1763643466000},"score":1,"resource":{"primary":{"URL":"https:\/\/ugeskriftet.dk\/videnskab\/V04250323"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":22,"URL":"https:\/\/doi.org\/10.61409\/v04250323","relation":{},"ISSN":["0041-5782","1603-6824"],"issn-type":[{"type":"print","value":"0041-5782"},{"type":"electronic","value":"1603-6824"}],"subject":[],"published":{"date-parts":[[2025,11,17]]}}}